Sea Limited Receives Rating Boost and Raised Price Target from Macquarie
PorAinvest
martes, 12 de agosto de 2025, 7:29 pm ET1 min de lectura
AMN--
The company reported an adjusted EPS of $0.30, surpassing the forecasted $0.18, and revenue of $658.18 million, which was slightly above the projected $652.63 million [2]. Despite these positive earnings figures, AMN Healthcare's stock has experienced a decline, reflecting broader market uncertainties and concerns over a net loss. The company's stock has declined over 70% in the past year, though InvestingPro analysis suggests the company is currently undervalued based on its Fair Value assessment [1].
BMO Capital noted that recent government policies and macroeconomic volatility have negatively impacted healthcare staffing volumes, with Academic Medical Centers that rely on federal funding experiencing the most significant declines [1]. The research firm reported some stabilization in July, but AMN's third-quarter 2025 revenue guidance came in below consensus expectations due to the volume decreases [1].
Citizens JMP, another analyst firm, also lowered AMN Healthcare's price target to $22 from $33 while maintaining an Outperform rating. The analyst is encouraged by stable Q3 order and extension trends, despite near-term staffing trends remaining choppy. The longer-term risk/reward profile of shares remains attractive, the firm says [3].
AMN Healthcare's stock price currently stands at $16.50, reflecting a decrease of 4.29% with a change of $0.74. The stock has fluctuated between a low of $16.45 and a high of $17.59 during the day. Over the past year, AMN has reached a high of $59.19 and a low of $14.87. The company's market capitalization is approximately $631.7 million, with a trading volume of 574,738 shares on the NYSE [3].
Investors continue to monitor these developments closely as they assess the company’s financial health. Despite the recent earnings beat and positive revenue figures, the company's stock experienced a decline, reflecting broader market uncertainties and concerns over a net loss. Analyst firms have not issued any recent upgrades or downgrades for AMN Healthcare.
References:
[1] https://www.investing.com/news/analyst-ratings/amn-healthcare-stock-price-target-lowered-to-22-from-27-at-bmo-capital-93CH-4183168
[2] https://finance.yahoo.com/news/amn-healthcare-services-second-quarter-133140781.html
[3] https://site.financialmodelingprep.com/market-news/amn-healthcare-nyse-amn-financial-analysis-price-target
BMO--
Citizens JMP lowered AMN Healthcare's price target to $22 from $33 and maintained an Outperform rating. The analyst is encouraged by stable Q3 order and extension trends, despite near-term staffing trends remaining choppy. The longer-term risk/reward profile of shares remains attractive, the firm says.
AMN Healthcare (NYSE: AMN) has seen a significant shift in its price target following the company's second-quarter 2025 earnings report. BMO Capital recently lowered its price target on AMN Healthcare from $27 to $22, while maintaining an Outperform rating [1]. This move comes on the heels of AMN Healthcare's earnings report, which exceeded consensus estimates despite a year-over-year decline in earnings per share (EPS) and revenues.The company reported an adjusted EPS of $0.30, surpassing the forecasted $0.18, and revenue of $658.18 million, which was slightly above the projected $652.63 million [2]. Despite these positive earnings figures, AMN Healthcare's stock has experienced a decline, reflecting broader market uncertainties and concerns over a net loss. The company's stock has declined over 70% in the past year, though InvestingPro analysis suggests the company is currently undervalued based on its Fair Value assessment [1].
BMO Capital noted that recent government policies and macroeconomic volatility have negatively impacted healthcare staffing volumes, with Academic Medical Centers that rely on federal funding experiencing the most significant declines [1]. The research firm reported some stabilization in July, but AMN's third-quarter 2025 revenue guidance came in below consensus expectations due to the volume decreases [1].
Citizens JMP, another analyst firm, also lowered AMN Healthcare's price target to $22 from $33 while maintaining an Outperform rating. The analyst is encouraged by stable Q3 order and extension trends, despite near-term staffing trends remaining choppy. The longer-term risk/reward profile of shares remains attractive, the firm says [3].
AMN Healthcare's stock price currently stands at $16.50, reflecting a decrease of 4.29% with a change of $0.74. The stock has fluctuated between a low of $16.45 and a high of $17.59 during the day. Over the past year, AMN has reached a high of $59.19 and a low of $14.87. The company's market capitalization is approximately $631.7 million, with a trading volume of 574,738 shares on the NYSE [3].
Investors continue to monitor these developments closely as they assess the company’s financial health. Despite the recent earnings beat and positive revenue figures, the company's stock experienced a decline, reflecting broader market uncertainties and concerns over a net loss. Analyst firms have not issued any recent upgrades or downgrades for AMN Healthcare.
References:
[1] https://www.investing.com/news/analyst-ratings/amn-healthcare-stock-price-target-lowered-to-22-from-27-at-bmo-capital-93CH-4183168
[2] https://finance.yahoo.com/news/amn-healthcare-services-second-quarter-133140781.html
[3] https://site.financialmodelingprep.com/market-news/amn-healthcare-nyse-amn-financial-analysis-price-target

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios